title: Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
abstract: A significant proportion of HIV patients, ranging between 5-67%, are co-infected with hepatitis B virus (HBV). Several studies suggest an increasing incidence of hepatocellular carcinoma (HCC) in HIV infected individuals. We report the case of a 69 years old male co infected with HBV and HIV who developed HCC. The patient was unfit for curative approach and he underwent three sessions of transcatheter arterial chemoembolisation (TACE). After the last session the disease assessment showed progression and sorafenib therapy was initiated. Highly active antiretroviral therapy (HAART) was continued during sorafenib treatment. The patient achieved a radiological complete response (CR) after 6 months of therapy and remained with no sign of HCC progression at subsequent assessment. Meanwhile, patient's HIV and HBV infections remained stable. Regarding toxicity the patient developed grade 3 hand foot skin reaction (HFSR) that required 50% dose reduction of sorafenib, grade 3 hypertension and grade 2 diarrhea. In conclusion this is the first case of successful treatment of HCC in a HIV-HBV co-infected patient and only the second report of the co administration of sorafenib with HAART.
authors.affiliation: Department of Medical Oncology, Democritus University of Thrace, 68100 Thrace, Alexandroupolis, Dragana, Greece. chelisleonidas@yahoo.gr
authors.forename: Leonidas
authors.initials: L
authors.lastname: Chelis
authors.forename: Napoleon
authors.initials: N
authors.lastname: Ntinos
authors.forename: Vasilios
authors.initials: V
authors.lastname: Souftas
authors.forename: Savas
authors.initials: S
authors.lastname: Deftereos
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Xenidis
authors.forename: Elen
authors.initials: E
authors.lastname: Chamalidou
authors.forename: Eustratios
authors.initials: E
authors.lastname: Maltezos
authors.forename: Stylianos
authors.initials: S
authors.lastname: Kakolyris
mesh_terms: D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001557:Benzenesulfonates / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D060085:Coinfection / Q000188:drug therapy / Q000821:virology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008113:Liver Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000008:administration & dosage*; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib
references.citation: N Engl J Med. 2008 Jul 24;359(4):378-90
references.pmid: 18650514
references.citation: Lancet Oncol. 2009 Jan;10(1):61-71
references.pmid: 19111246
references.citation: Gastroenterology. 2008 Dec;135(6):1972-83, 1983.e1-11
references.pmid: 18929564
references.citation: Invest New Drugs. 2010 Oct;28(5):535-42
references.pmid: 19554262
references.citation: Mol Cancer. 2010 Jan 27;9:19
references.pmid: 20105315
references.citation: Clin Cancer Res. 2010 Jan 15;16(2):390-7
references.pmid: 20068087
references.citation: Antiviral Res. 2010 Jan;85(1):303-15
references.pmid: 19887087
references.citation: Mol Cancer. 2009 Apr 22;8:26
references.pmid: 19386116
references.citation: World J Gastroenterol. 2008 Mar 21;14(11):1657-63
references.pmid: 18350596
references.citation: JAMA. 2008 Jul 2;300(1):51-9
references.pmid: 18594040
references.citation: AIDS. 2008 Oct 18;22(16):2135-41
references.pmid: 18832877
references.citation: Lancet Oncol. 2009 Jan;10(1):25-34
references.pmid: 19095497
references.citation: Antivir Ther. 2009;14(2):155-64
references.pmid: 19430090
references.citation: Clin Cancer Res. 2006 Mar 15;12(6):1883-96
references.pmid: 16551874
references.citation: J Hepatol. 2009 Apr;50(4):736-45
references.pmid: 19231018
references.citation: Arch Intern Med. 2006 Aug 14-28;166(15):1632-41
references.pmid: 16908797
references.citation: Oncologist. 2010;15(2):142-5
references.pmid: 20142333
references.citation: J Hematol Oncol. 2008 Oct 17;1:18
references.pmid: 18928548
references.citation: Hepatology. 2005 Nov;42(5):1208-36
references.pmid: 16250051
references.citation: Gastroenterology. 2004 Nov;127(5 Suppl 1):S303-9
references.pmid: 15508098